MX2022007798A - Metodo de produccion de conjugado de anticuerpo-farmaco a base de eribulina. - Google Patents
Metodo de produccion de conjugado de anticuerpo-farmaco a base de eribulina.Info
- Publication number
- MX2022007798A MX2022007798A MX2022007798A MX2022007798A MX2022007798A MX 2022007798 A MX2022007798 A MX 2022007798A MX 2022007798 A MX2022007798 A MX 2022007798A MX 2022007798 A MX2022007798 A MX 2022007798A MX 2022007798 A MX2022007798 A MX 2022007798A
- Authority
- MX
- Mexico
- Prior art keywords
- drug conjugate
- formula
- integer
- antibody
- eribulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
Abstract
La presente invención proporciona un método para producir un conjugado de anticuerpo-fármaco representado por la fórmula (I) (ver Fórmula) [en donde: Ab representa un anticuerpo o un fragmento de unión a antígeno de este; D representa eribulina; m es un número entero de 1-10; y p es un número entero de 1-8], comprendiendo el método un paso 1 de hacer reaccionar eribulina o una sal de esta con un compuesto representado por la fórmula (A) (ver Fórmula) [en donde: m es un número entero de 1-10; y X representa un grupo fenoxi o un grupo nitrofenoxi] para dar un compuesto representado por la fórmula (B) (ver Fórmula) [en donde m es un número entero de 1-10], y un paso 2 de hacer reaccionar el compuesto representado por la fórmula (B) con el Ab para dar el conjugado de anticuerpo-fármaco representado por la fórmula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019231938 | 2019-12-23 | ||
PCT/JP2020/047706 WO2021132166A1 (ja) | 2019-12-23 | 2020-12-21 | エリブリンをベースとする抗体-薬物コンジュゲートの製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022007798A true MX2022007798A (es) | 2022-07-19 |
Family
ID=76575922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022007798A MX2022007798A (es) | 2019-12-23 | 2020-12-21 | Metodo de produccion de conjugado de anticuerpo-farmaco a base de eribulina. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230074385A1 (es) |
EP (1) | EP4088739A1 (es) |
JP (1) | JPWO2021132166A1 (es) |
KR (1) | KR20220120586A (es) |
CN (1) | CN114828895A (es) |
AU (1) | AU2020414996A1 (es) |
BR (1) | BR112022012546A2 (es) |
CA (1) | CA3164797A1 (es) |
IL (1) | IL293040A (es) |
MX (1) | MX2022007798A (es) |
WO (1) | WO2021132166A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023001300A1 (zh) * | 2021-07-22 | 2023-01-26 | 上海森辉医药有限公司 | 艾日布林衍生物的药物偶联物 |
WO2023016488A1 (zh) * | 2021-08-13 | 2023-02-16 | 昆山新蕴达生物科技有限公司 | 一种基于微管抑制剂的抗体偶联药物 |
TW202327661A (zh) * | 2021-09-16 | 2023-07-16 | 大陸商正大天晴藥業集團股份有限公司 | 抗her3抗體藥物偶聯物及其組合物和用途 |
WO2023103854A1 (zh) * | 2021-12-09 | 2023-06-15 | 昆山新蕴达生物科技有限公司 | 一种亲和力改善的抗体-药物偶联物、其制备方法及应用 |
WO2023124963A1 (zh) * | 2021-12-27 | 2023-07-06 | 昆山新蕴达生物科技有限公司 | 一种可逆反应减少的抗体-药物偶联物,其制备方法及应用 |
WO2023155808A1 (zh) * | 2022-02-16 | 2023-08-24 | 苏州宜联生物医药有限公司 | 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
US7452539B2 (en) * | 2001-12-19 | 2008-11-18 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
SI1791565T1 (sl) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cisteinsko konstruirana protitelesa in konjugati |
SG11201401452PA (en) * | 2011-11-17 | 2014-06-27 | Pfizer | Cytotoxic peptides and antibody drug conjugates thereof |
AU2014284212B2 (en) * | 2013-06-20 | 2019-09-12 | Eisai, Inc. | Methods for treatment of ovarian cancer |
MX2017012102A (es) * | 2015-03-20 | 2018-01-12 | Pfizer | Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti. |
KR102445255B1 (ko) | 2016-03-02 | 2022-09-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 에리불린-기반 항체-약물 콘주게이트 및 사용 방법 |
AR113224A1 (es) * | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
CA3099920A1 (en) * | 2018-06-01 | 2019-12-05 | Eisai R&D Management Co., Ltd. | Splicing modulator antibody-drug conjugates and methods of use |
-
2020
- 2020-12-21 BR BR112022012546A patent/BR112022012546A2/pt unknown
- 2020-12-21 WO PCT/JP2020/047706 patent/WO2021132166A1/ja unknown
- 2020-12-21 IL IL293040A patent/IL293040A/en unknown
- 2020-12-21 KR KR1020227022013A patent/KR20220120586A/ko unknown
- 2020-12-21 CN CN202080088854.3A patent/CN114828895A/zh active Pending
- 2020-12-21 JP JP2021567445A patent/JPWO2021132166A1/ja active Pending
- 2020-12-21 MX MX2022007798A patent/MX2022007798A/es unknown
- 2020-12-21 EP EP20905452.7A patent/EP4088739A1/en active Pending
- 2020-12-21 AU AU2020414996A patent/AU2020414996A1/en active Pending
- 2020-12-21 CA CA3164797A patent/CA3164797A1/en active Pending
- 2020-12-21 US US17/757,825 patent/US20230074385A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL293040A (en) | 2022-07-01 |
KR20220120586A (ko) | 2022-08-30 |
CA3164797A1 (en) | 2021-07-01 |
AU2020414996A1 (en) | 2022-07-14 |
CN114828895A (zh) | 2022-07-29 |
BR112022012546A2 (pt) | 2022-09-06 |
JPWO2021132166A1 (es) | 2021-07-01 |
EP4088739A1 (en) | 2022-11-16 |
WO2021132166A1 (ja) | 2021-07-01 |
US20230074385A1 (en) | 2023-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022007798A (es) | Metodo de produccion de conjugado de anticuerpo-farmaco a base de eribulina. | |
CL2022001731A1 (es) | Inhibidores de egfr. | |
MX2022011283A (es) | Compuestos pirimidoheterocíclicos y aplicación de los mismos. | |
EA200870321A1 (ru) | Способ получения 4-оксохинолинового соединения | |
IN2014CN00532A (es) | ||
MX2022008474A (es) | Conjugado de anticuerpo anti-trop-2-analogo de exatecan y uso medico del mismo. | |
WO2021212049A3 (en) | Anti-sars-cov-2 monoclonal antibodies | |
NZ602676A (en) | Anti-vla-4 antibodies | |
MX2022011769A (es) | Metodo de preparacion de medicamento de conjugado de anticuerpo. | |
BR112022000598A2 (pt) | Composto de ureia para antagonização de receptor de lpa1 | |
EA200300804A1 (ru) | Усовершенствованный способ получения карбапенема | |
WO2021205388A3 (en) | An improved process for the preparation of semaglutide side chain | |
MX2023004054A (es) | Anticuerpos anti-dectina 1 y metodos de uso de los mismos. | |
WO2019207257A8 (fr) | Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices | |
CR20230470A (es) | Conjugados de anticuerpo anti-nectina-4 y exatecano. | |
JOP20210333A1 (ar) | جسم مضاد لـ EphA4 | |
TW200510305A (en) | Process for the preparation of CPLA2 inhibitors | |
EP4169925A3 (en) | Process to make n-substituted tetrahydrothienopyridine derivatives | |
EA200400069A1 (ru) | Способ получения производных циклогексанола | |
ZA202210724B (en) | Anti-psma antibody-exatecan analogue conjugate and medical use thereof | |
WO2022053651A3 (en) | Antibody fragment against fap | |
EA200400739A1 (ru) | Способ получения производных [1,4,5]оксадиазепина | |
WO2021236998A3 (en) | Potent neutralizing antibodies against sars-cov-2, generation and uses thereof | |
MX2022002941A (es) | Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo. | |
EA202192639A1 (ru) | Способ получения сипонимода и его промежуточного соединения |